BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 39,000 Shares of Company Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 39,000 shares of the stock in a transaction dated Thursday, September 24th. The shares were sold at an average price of $98.99, for a total value of $3,860,610.00. Following the completion of the transaction, the chief executive officer directly owned 341,209 shares in the company, valued at $33,776,278.91. This represents a 10.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total value of $2,982,000.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The shares were sold at an average price of $100.72, for a total value of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The stock was sold at an average price of $97.81, for a total transaction of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $96.22, for a total transaction of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.60, for a total transaction of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The shares were sold at an average price of $96.09, for a total transaction of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total transaction of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total transaction of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total transaction of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total transaction of $1,974,355.00.

BioNTech Price Performance

NASDAQ:BNTX opened at $99.26 on Friday. The firm’s fifty day moving average is $98.03 and its two-hundred day moving average is $94.76. The firm has a market cap of $25.10 billion, a price-to-earnings ratio of -12.68 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. BioNTech SE Sponsored ADR has a one year low of $79.52 and a one year high of $124.00.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The company had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business’s quarterly revenue was down 59.5% compared to the same quarter last year. During the same period last year, the firm earned ($1.60) EPS. Research analysts expect that BioNTech SE Sponsored ADR will post -6.37 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Monaco Asset Management SAM acquired a new stake in shares of BioNTech during the fourth quarter worth $1,594,000. Hsbc Holdings PLC acquired a new position in BioNTech in the 4th quarter valued at $4,969,000. Bank of America Corp DE raised its position in BioNTech by 22.6% during the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after buying an additional 166,432 shares during the last quarter. BNP Paribas Financial Markets raised its position in BioNTech by 43.0% during the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after buying an additional 474,796 shares during the last quarter. Finally, Amundi lifted its stake in shares of BioNTech by 24.5% in the 1st quarter. Amundi now owns 129,513 shares of the company’s stock worth $11,511,000 after acquiring an additional 25,506 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BNTX. Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. BMO Capital Markets downgraded shares of BioNTech from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $128.00 to $105.00 in a report on Tuesday, September 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research note on Monday, July 6th. UBS Group restated a “buy” rating on shares of BioNTech in a research report on Wednesday, September 16th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a research note on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and an average target price of $126.00.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.